A new drug has been approved for general use by the US Food and Drug Administration (FDA) which allows people with multiple sclerosis (MS) to walk at a much faster pace.
The new treatment, Ampyra (dalfampridine), was found in clinical trials to encourage boosted walking speeds when compared to those treated with a basic placebo, the FDA concluded.
Manufactured by Biogen Idec, it will be the first drug to treat this situation in those with the early stages of the disease, with the company applying for a licence to produce the drug in the UK.
Alfred Sandrock, senior vice-president of neurology research and development at Biogen Idec, said: "For people with MS, impaired walking ability is one of the most common and concerning aspects of the disease.
"Ampyra may be an important therapy in reducing the impact of this debilitating condition."
Earlier this week, Tysabri - which is used to fight conditions brought about by MS - was supported by the European Medicines Agency as the benefits of the medicine outweigh its risks for patients with very active relapsing-remitting multiple sclerosis.
Read about Barchester expertise in offering multiple sclerosis support.